Background
Methods
PIF peptide synthesis
Endometrial cell cultures
Microarray analysis
Statistical analysis: gene pathway (MetaCore)
Statistical analysis of neural gene ranking (Ingenuity)
Mass spectrometry analysis
Results
PIF regulates neurodevelopmental gene expression at embryo implantation phase (HESC) and throughout the first trimester (FTDC)
HESC | FTDC | ||
---|---|---|---|
TGFβ | |||
TLX2 | 13.8 | SMAD1 | 53.4 |
CREBBP | -2.2 | SMAD6 | 2.7 |
SMAD6 | -2.4 | SMAD2 | 2.5 |
TGFBR1 | -2.6 | ACVR1C | -3.1 |
INHBC | -4.6 | ||
EPH | |||
EPHA10 | 9.0 | EPHA5 | 7.8 |
CDC42 | 3.7 | RAP1A | 2.3 |
EPHA5 | 2.4 | EGF | 2.2 |
ITSN1 | -2.3 | AKT3 | 2.2 |
PDGFC | -2.6 | STAT3 | -2.1 |
PTK2 | -3.1 | ANGPT1 | -2.3 |
EPHA6 | -3.1 | RAC1 | -2.4 |
AKT2 | -5.6 | ||
WNT | |||
MDM2 | 5.0 | SOX17 | 2.5 |
LEF1 | 2.2 | AKT3 | 2.2 |
CREBBP | -2.2 | KREMEN1 | -2.3 |
TLE4 | -2.3 | CSNK2A1 | -2.3 |
CDH2 | -2.5 | PPP2R1B | -2.5 |
TGFBR1 | -2.6 | ACVR1C | -3.1 |
WNT16 | -3.9 | PPP2R2C | -6.6 |
AKT2 | -5.6 | ||
RARA | -9.4 |
PIF’s neurotrophic effects: Ingenuity analysis of neural-related pathways in HESC and FTDC
Axonal guidance signaling 9.20E - 02 | Neuregulin signaling 8.70E - 02 | Synaptic long-term potentiation 7.46E - 02 | Amyotrophic lateral sclerosis signaling 6.94E - 02 | Synaptic long-term depression 4.84E - 02 | Huntington’s disease signaling 4.90E - 02 | Oxidative phosphorylation 3.47E - 02 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CDC42 | 3.7 | PTEN | 2.6 | CAMK2B | 2 | RAB5A | 3.9 | PRKG1 | -2.5 | CREBBP | -2.1 | ATP6V0D2 | 3.5 |
EPHA5 | 2.3 | ERBB2IP | -2.2 | CAMK2D | -2.1 | GRIK5 | 2.3 | PRKCB1 | -4.4 | PIK3CA | -2.4 | PPA2 | 3.5 |
SEMA4C | 2 | PDK1 | -3 | CREBBP | -2.1 | GRIK2 | -2 | GRM1 | -17 | HDAC9 | -3.7 | CYB5A | 3.1 |
PDGFC | -2.5 | ERBB3 | -3.2 | PRKCB1 | -4.4 | PIK3CA | -2.4 | CASP8 | -4.2 | NDUFA10 | 2.1 | ||
SEMA6A | -4.5 | PRKCB1 | -4.4 | GRM1 | -17 | BCL2 | -21 | PRKCB1 | -4.4 | NDUFA5 | -2.1 | ||
SEMA4D | -6 | AKT2 | -5.6 | AKT2 | -5.6 | ||||||||
SEMA3D | -10 | GRM1 | -17 | ||||||||||
SEMA3C | -11 |
Amyloid processing 8.33E - 02 | Amyotrophic lateral sclerosis signaling 8.33E - 02 | Huntington’s disease signaling 7.69E - 02 | Synaptic long-term depression 6.45E - 02 | Axonal guidance signaling 5.75E - 02 | Neurotrophin/TRK signaling 4.00E - 02 | Neuregulin signaling 1.16E - 01 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
AKT3 | 2.1 | GRIK2 | 2.5 | BDNF | 3 | GNA12 | -2 | ARHGEF12 | 9 | BDNF | 3 | NRG1 | 5 |
CDK5R1 | 2 | RAC1 | -2.4 | AKT3 | 2.1 | PPP2R1B | -2.5 | EPHA5 | 7.8 | CSNK2A1 | -2.3 | PLCG2 | 3.1 |
CSNK2A1 | -2.3 | SLC1A2 | -3 | EGF | 2.1 | GUCY1A3 | -4.9 | GLI2 | 6.1 | EGF | 2.1 | ||
PPP3CA | -9.2 | POLR2J2 | 2 | PPP2R2C | -6.5 | NRP1 | 4.2 | AKT3 | 2.1 | ||||
BCL2 | -27 | CDK5R1 | 2 | BDNF | 3 | CDK5R1 | 2 | ||||||
TCERG1 | -2 | RAP1A | 2.2 | ADAM17 | -2 | ||||||||
SNCA | -2 | AKT3 | 2.1 | PDK1 | -5.2 | ||||||||
CLTC | 3.1 | EGF | 2.1 | EGFR | -24.5 | ||||||||
RPH3A | -3.1 | DOCK1 | 2.1 | ||||||||||
EGFR | -24.5 | SEMA6D | 2.1 | ||||||||||
SLIT1 | 2.1 | ||||||||||||
RAC1 | -2.4 | ||||||||||||
ROBO1 | -2.5 | ||||||||||||
DPYSL5 | -4.6 | ||||||||||||
PPP3CA | -9.2 |
PIF’s effects on HESC and FTDC—pathways and protection against post-natal disease—MetaCore analysis
GeneGo pathway maps | GeneGo process networks | GO processes | GeneGo diseases (by biomarker) | ||||
---|---|---|---|---|---|---|---|
Name | p value | Name | p value | Name | p value | Name | p value |
Development_angiotensin signaling via beta-arrestin | 0.001218 | Neurophysiological process_transmission of nerve impulse_ | 1.114E - 06 | Nervous system development | 1.736E - 16 | Autistic disorder | 4.026E - 14 |
Development_regulation of epithelial-to-mesenchymal transition (EMT) | 0.001379 | Muscle contraction | 0.0005106 | Positive regulation of biological process | 7.282E - 16 | Child development disorders, pervasive | 4.887E - 14 |
G-protein signaling_RhoB regulation pathway | 0.003256 | Cytoskeleton_regulation of cytoskeleton rearrangement | 0.0009131 | Cell communication | 5.021E - 15 | Mood disorders | 2.655E - 09 |
Cell adhesion_tight junctions | 0.004814 | Development_neurogenesis: axonal guidance | 0.001197 | Regulation of transport | 9.227E - 15 | Stress | 2.787E - 09 |
Muscle contraction_GPCRs in the regulation of smooth muscle tone | 0.005149 | Reproduction_GnRH signaling pathway | 0.008079 | Anatomical structure development | 1.207E - 14 | Mental disorders diagnosed in childhood | 6.579E - 09 |
Cytoskeleton remodeling_TGF, WNT, and cytoskeletal remodeling | 0.005462 | Cell adhesion_cell junctions | 0.01565 | Regulation of localization | 1.48E - 14 | Aortic diseases | 6.6E - 09 |
Atherosclerosis_role of ZNF202 in regulation of expression of genes involved in atherosclerosis | 0.007208 | Signal transduction_cholecystokinin signaling | 0.02107 | Regulation of amine transport | 1.744E - 14 | Aortic aneurysm | 6.801E - 09 |
Transcription_CREB pathway | 0.009855 | Signal transduction_TGF-beta, GDF, and activin signaling | 0.02518 | Transmission of nerve impulse | 2.15E - 14 | Craniomandibular disorders | 1.025E - 08 |
Cell adhesion_role of CDK5 in cell adhesion | 0.01212 | Signal transduction_WNT signaling | 0.02811 | Positive regulation of cellular process | 2.762E - 14 | Temporomandibular joint disorders | 1.025E - 08 |
Development_TGF-beta-dependent induction of EMT via MAPK | 0.01239 | Reproduction_gonadotropin regulation | 0.02941 | Regulation of multicellular organismal process | 3.763E - 14 | Mandibular diseases | 5.041E - 08 |
HESC | FTDC | |||
---|---|---|---|---|
Ontology | Upregulated processes | Downregulated processes | Upregulated processes | Downregulated processes |
GeneGo Pathway Maps | G-protein signaling_RhoB regulation pathway | Development_TGF-beta-dependent induction of EMT via MAPK | Cell cycle_role of 14-3-3 proteins in cell cycle regulation | Androstenedione and testosterone biosynthesis and metabolism p.2 |
Development_angiotensin signaling via beta-Arrestin | Immune response_CD137 signaling in immune cell | Development_EGFR signaling via PIP3 | Acetaminophen metabolism | |
G-protein signaling_RhoA regulation pathway | Development_regulation of epithelial-to-mesenchymal transition (EMT) | Apoptosis and survival_role of CDK5 in neuronal death and survival | 1-naphthylamine and 1-nitronaphthalene metabolism | |
Immune response_antiviral actions of Interferons | Cell adhesion_role of tetraspanins in the integrin-mediated cell adhesion | Development_neurotrophin family signaling | Immune response_IL-15 signaling via JAK-STAT cascade | |
Immune response_IFN alpha/beta signaling pathway | Development_beta-adrenergic receptors transactivation of EGFR |
Neurophysiological process_receptor-mediated axon growth repulsion
| 2-naphthylamine and 2-nitronaphthalene metabolism | |
Development_signaling of beta-adrenergic receptors via beta-arrestins | Development_gastrin in differentiation of the gastric mucosa | Role of alpha-6/beta-4 integrins in carcinoma progression | Estradiol metabolism | |
G-protein signaling_regulation of CDC42 activity |
Neurophysiological process_receptor-mediated axon growth repulsion
| Cell cycle_cell cycle (generic schema) |
G-protein signaling_regulation of RAC1 activity
| |
Muscle contraction_GPCRs in the regulation of smooth muscle tone | Transcription_androgen receptor nuclear signaling | Development_ERK5 in cell proliferation and neuronal survival | Immune response_IL-15 signaling via JAK-STAT cascade | |
Neurophysiological process_EphB receptors in dendritic spine morphogenesis and synaptogenesis | Regulation of metabolism_triiodothyronine and thyroxine signaling | Cell cycle_initiation of mitosis | Benzo [a] pyrene metabolism | |
G-protein signaling_regulation of RAC1 activity
| Cell adhesion_integrin-mediated cell adhesion and migration | G-protein signaling_K-RAS regulation pathway | Apoptosis and survival_HTR1A signaling |
GeneGo pathway maps | GeneGo process networks | GO processes | GeneGo diseases (by biomarker) | ||||
---|---|---|---|---|---|---|---|
Name | p value | Name | p value | Name | p value | Name | p value |
Acetaminophen metabolism | 0.00001014 | Reproduction_feeding and neurohormones signaling | 0.0004425 | Multicellular organismal process | 2.563E - 14 | Skin and connective tissue diseases | 1.006E - 10 |
Androstenedione and testosterone biosynthesis and metabolism p.2 | 0.00003172 | Development_blood vessel morphogenesis | 0.003215 | Regulation of biological quality | 9.359E - 14 | Skin diseases | 1.014E - 09 |
Cell cycle_role of 14-3-3 proteins in cell cycle regulation | 0.00003564 | Muscle contraction | 0.003752 | Positive regulation of biological process | 1.611E - 13 | Neoplasms by histologic type | 2.396E - 09 |
Androstenedione and testosterone biosynthesis and metabolism p.2/rodent version | 0.0000375 | Cell cycle_meiosis | 0.00434 | Regulation of multicellular organismal process | 3.408E - 13 | Myoepithelioma | 1.598E - 08 |
Development_EGFR signaling via PIP3 | 0.00004489 | Cell cycle_G2-M | 0.005763 | Regulation of localization | 4.975E - 13 | Neoplasms, glandular, and epithelial | 2.089E - 08 |
Cell cycle_initiation of mitosis | 0.00006886 | Development_ossification and bone remodeling | 0.007848 | Regulation of secretion | 8.326E - 13 | Capillary leak syndrome | 6.196E - 08 |
Development_prolactin receptor signaling | 0.00007228 | DNA damage_DBS repair | 0.00865 | Intracellular signaling cascade | 1.943E - 12 | Breast neoplasms | 8.058E - 08 |
Apoptosis and survival_role of CDK5 in neuronal death and survival | 0.0003167 | Development_regulation of angiogenesis | 0.01318 | Cellular calcium ion homeostasis | 2.698E - 12 | Breast diseases | 8.287E - 08 |
Estradiol metabolism | 0.0003642 | Reproduction_male sex differentiation | 0.01432 | Calcium ion homeostasis | 4.215E - 12 | Schizophrenia | 1.035E - 07 |
G-protein signaling_regulation of RAC1 activity | 0.0004169 | Translation_regulation of initiation | 0.0149 | Cellular metal ion homeostasis | 4.501E - 12 | Connective tissue diseases | 1.222E - 07 |
Similarity between PIF’s effect on HESC and FTDC
Interactome analysis of genes affected by PIF
HESC | FTDC | ||||
---|---|---|---|---|---|
HUB | Number of interactions with interactome (total hubs = 21,579) | Number of interaction with PIF-HESC genes (total hubs = 363) | HUB | Number of interactions with interactome (total hubs = 21,579) | Number of interaction with PIF-FTDC genes (total hubs = 384) |
ATBF1 | 19 | 3 | PEA3 | 239 | 12 |
NK31 | 37 | 4 | STAT3 | 603 | 26 |
Plexin A4 | 12 | 3 | c-Rel | 382 | 16 |
HIPK2 | 60 | 7 | CDK1 | 389 | 22 |
SYNJ2BP | 37 | 5 | UGT1A6 | 9 | 3 |
FUS | 68 | 7 | UGT1A1 | 31 | 5 |
Beta-fodrin | 65 | 8 |
HESC | FTDC | ||||||
---|---|---|---|---|---|---|---|
Process | Percentage | p value | Expressed genes | Process | Percentage | p value | Expressed genes |
Regulation of transcription, DNA-dependent | 74.07 | 1.216E - 28 | NKX3-1, SP3, SOX2, STAT3, ZFHX3 | Response to chemical stimulus | 69.84 | 4.365E - 24 | |
Regulation of RNA metabolic process | 74.07 | 3.141E - 28 | Response to organic substance | 57.14 | 4.814E - 24 | UGT1A1, STAT3 | |
Regulation of transcription from RNA polymerase II promoter | 59.26 | 4.227E - 28 | STAT3 | Positive regulation of biological process | 71.43 | 5.785E - 24 | |
Positive regulation of gene expression | 57.41 | 6.061E - 28 | MDM2 | Positive regulation of macromolecule metabolic process | 50.79 | 2.78E - 21 | |
Positive regulation of transcription | 55.56 | 4.355E - 27 | NKX3-1, SOX2, STAT3 | Organ development | 63.49 | 3.189E - 21 | |
Transcription | 74.07 | 1.364E - 26 | NKX3-1, SP3, SOX2, STAT3, HIPK2, ZFHX3 | Positive regulation of cellular process | 65.08 | 3.603E - 21 | |
Regulation of transcription | 79.63 | 2.039E - 26 | NKX3-1, SP3, SOX2, STAT3, HIPK2, ZFHX3 | Positive regulation of cellular metabolic process | 50.79 | 1.333E - 20 | |
Positive regulation of nucleobase, nucleoside, nucleotide, and nucleic acid metabolic process | 55.56 | 1.925E - 25 | Positive regulation of gene expression | 42.86 | 4.074E - 20 | CDK1 | |
Positive regulation of transcription, DNA-dependent | 50 | 3.096E - 25 | HIPK2 | Positive regulation of metabolic process | 50.79 | 5.766E - 20 | |
Positive regulation of RNA metabolic process | 50 | 3.955E - 25 | Response to stimulus | 77.78 | 4.007E - 19 | ||
Positive regulation of macromolecule biosynthetic process | 55.56 | 4.246E - 25 | System development | 66.67 | 4.06E - 19 | ||
Positive regulation of nitrogen compound metabolic process | 55.56 | 5.851E - 25 | Positive regulation of transcription, DNA-dependent | 38.1 | 4.184E - 19 | TP63, REL |